`
`PCT/U82008/071020
`
`We claim:
`
`38
`
`Claims
`
`1. A polymer comprising a plurality of repeating dicnc monomers having coupled
`
`thereto at least one biologically active molecule through at least one non—amide linking
`
`moiety (linker).
`
`2. The polymer of claim 1, wherein the linker is least one moiety selected from the
`
`group consisting of an ester, carbonate, carbomate, and ether.
`
`3. The polymer of claim 1, wherein linker comprises an ether moiety and carbamate
`
`moiety.
`
`4. The polymer of claim 1, wherein the diene monomer is selected from the group
`
`consisting of3,3 acid, 6,6 acid, 9,9 acid, and 18,18 acid.
`
`5. The polymer of claim 1, wherein the monomer further comprises at least one
`
`spacer interposed between the biologically active molecule and the linker.
`
`6. The polymer of claim 5, wherein the spacer is at least one moiety selected from the
`
`group consisting ofmethoxy and glycol.
`
`7. The polymer of claim 6, wherein the spacer is at least one ethylene glycol moiety.
`
`8. The polymer of claim 6, wherein the spacer is diethylene glycol or triethylene
`
`glycol.
`
`9. The polymer of‘claim 1, wherein the spacer is at least one alkyl or diol moiety.
`
`10. The polymer of claim 1, wherein the at least one linker, the at least one spacer, or
`
`both are degradable by enzymatic cleavage, chemical hydrolysis, or both.
`
`
`
`WO 2009/015274
`
`PCT/U82008/071020
`
`39
`
`l l. The polymer of claim 1, wherein the biologically active molecule is selected from
`
`the group consisting of analgesics, anesthetics, anti-inflammatory agents, anthelmintics, anti—
`
`arrhythmic agents, antiasthma agents, antibiotics (including penicillins), anticancer agents
`
`(including Taxol),
`
`anticoagulants,
`
`antidepressants,
`
`antidiabetic
`
`agents,
`
`antiepileptics,
`
`antihistamines,
`
`antitussives,
`
`antihyp ertensive
`
`agents,
`
`antimuscarini c
`
`agents,
`
`antimycobacterial
`
`agents,
`
`antineoplastic
`
`agents,
`
`antioxidant
`
`agents,
`
`antipyretics,
`
`immunosupprcssants,
`
`immunostimulants, antithyroid agents, antiviral agents, anxiolytic
`
`sedatives (hypnotics and neuroleptics), astringents, bacteriostatic agents, beta—adrenoceptor
`
`blocking agents, blood products and substitutes, bronchodilators, buffering agents, cardiac
`
`inotropic agents, chemotherapeutics, contrast media, corticosteroids, cough suppressants
`
`(expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics,
`
`dopaniinergics (antiparkinsonian agents), free radical scavenging agents, growth factors,
`
`haemostatics,
`
`immunological agents,
`
`lipid regulating agents, muscle relaxants, proteins,
`
`peptides
`
`and
`
`polypeptides, » parasympathomimetics,
`
`parathyroid
`
`calcitonin
`
`and
`
`biphosphonates, pesticides, prostaglandins, radio—phannaceuticals, hormones, sex hormones
`
`(including steroids),
`
`time release binders, anti-allergic agents, stimulants and anoretics,
`
`steroids, sympathomimetics, thyroid agents, vaccines, vasodilators, and xanthines.
`
`12. A pharmaceutical composition comprising a polymer of claim 1; and a
`
`pharmaceutically acceptable carrier.
`
`13. A method for making a polymer of claim 1, comprising providing diene
`
`monomers coupled to at least one biologically active molecule through at least one non—
`
`amide linking moiety (linker); and polymerizing the monomers to produce the polymer.
`
`l4, The method of claim 13, wherein said providing comprises coupling the at least
`
`one biologically active molecule to the diene through at least one linker.
`
`15, A method for delivering a biologically active molecule to a subject, comprising
`
`administering a polymer of claim 1 to the subject.
`
`l6. A device comprising a polymer of claim 1.
`
`
`
`WO 2009/015274
`
`PCT/U82008/071020
`
`4O
`
`17. The device of claim 16, wherein the device comprises one or more substrates
`
`(surfaces) coated with the polymer or coated with a composition comprising the polymer,
`
`18. The device of claim 16, wherein the device is an implantable or deployable
`
`medical device.
`
`